Single Dose of China’s Ad5-nCoV COVID-19 Vaccine Is Safe and Effective in Phase 3 Trial

The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective against severe COVID-19 beginning 28 days post-vaccination, according to...

The post Single Dose of China’s Ad5-nCoV COVID-19 Vaccine Is Safe and Effective in Phase 3 Trial appeared first on SciTechDaily.

from SciTechDaily https://ift.tt/3qEVB8f